DaVita Inc. $DVA Shares Sold by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS AM has reduced its stock holdings in DaVita Inc. by 3.8%, owning approximately $68.58 million worth of shares after selling 17,755 shares in the first quarter.
• DaVita reported $2.95 earnings per share (EPS) for the last quarter, surpassing estimates and showing a 6.1% year-over-year revenue increase.
• Several institutional investors increased their stakes in DaVita, with notable increases from UMB Bank and the National Pension Service, further indicating strong interest in the company.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC decreased its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 3.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 448,291 shares of the company's stock after selling 17,755 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.59% of DaVita worth $68,575,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. MBB Public Markets I LLC acquired a new position in shares of DaVita in the first quarter worth about $317,000. Aristeia Capital L.L.C. acquired a new position in shares of DaVita in the first quarter worth about $290,000. Caxton Associates LLP bought a new stake in DaVita in the first quarter valued at about $513,000. Goldman Sachs Group Inc. increased its holdings in DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company's stock valued at $27,403,000 after buying an additional 28,739 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in DaVita in the first quarter valued at about $364,000. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Performance

Shares of NYSE:DVA traded up $2.27 during trading on Thursday, hitting $130.27. 704,783 shares of the company traded hands, compared to its average volume of 703,704. The stock has a market capitalization of $9.31 billion, a price-to-earnings ratio of 12.81, a PEG ratio of 0.92 and a beta of 1.13. The business's fifty day moving average is $137.40 and its 200-day moving average is $141.09. DaVita Inc. has a one year low of $126.07 and a one year high of $179.60. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.70 by $0.25. The company had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The business's revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.00 earnings per share. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, equities analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on DVA shares. Bank of America lowered their price objective on DaVita from $145.00 to $140.00 and set an "underperform" rating for the company in a report on Wednesday, September 10th. Barclays lowered their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a report on Thursday, August 7th. Truist Financial set a $148.00 price objective on DaVita in a report on Friday, August 8th. Finally, Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, DaVita currently has an average rating of "Reduce" and a consensus target price of $158.00.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.50% of the company's stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.